Transaction Details

Footnotes

Reports the donation of 2,800 shares of common stock to a donor advised fund. | The total reported in Column 5 includes 2,205 restricted stock units and 278,286 shares of common stock. | Reports common stock issued upon settlement of performance restricted units granted to the reporting person in February 2021. The compensation committee of the Board of Directors determined that the performance criteria were met on March 2, 2026. The total reported in Column 5 includes 2,205 restricted stock units and 286,655 shares of common stock. | Reports common stock issued upon settlement of performance restricted units granted to the reporting person in March 2022. The compensation committee of the Board of Directors determined that the performance criteria were met on March 2, 2026. The total reported in Column 5 includes 2,205 restricted stock units and 287,582 shares of common stock. | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.87 - $101.97. | The total reported in Column 5 includes 2,205 restricted stock units and 284,189 shares of common stock. | Granted pursuant to the issuer's 2015 Equity Incentive Plan. | The options vest and become exercisable as to 34% of the underlying shares on January 1, 2018, 33% of the underlying shares on January 1, 2019 and 33% of the underlying shares on January 1, 2020. | The options vest and become exercisable as to 34% of the underlying shares on January 1, 2021, 33% of the underlying shares on January 1, 2022 and 33% of the underlying shares on January 1, 2023. | The options vest and become exercisable as to 34% of the underlying shares on January 1, 2022, 33% of the underlying shares on January 1, 2023 and 33% of the underlying shares on January 1, 2024. | The options vest and become exercisable as to 34% of the underlying shares on January 1, 2020, 33% of the underlying shares on January 1, 2021 and 33% of the underlying shares on January 1, 2022. | The options vest and become exercisable as to 34% of the underlying shares on January 1, 2019, 33% of the underlying shares on January 1, 2020 and 33% of the underlying shares on January 1, 2021.